- Conditions
- Urothelial Cancer
- Interventions
- Erdafitinib, Vinflunine, Docetaxel, Pembrolizumab, Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)
- Drug · Device
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 629 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 26
- States / cities
- Anchorage, Alaska • Sacramento, California • St. Helena, California + 22 more
Location Directory
Clinical trials in Atlanta, Georgia
This page shows live ClinicalTrials.gov search results for Atlanta, Georgia, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
13075
Shown on this page
12
Current sort
Recently updated
Location scope
Atlanta, GA
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 577–588 of 13,075 matching trials in Atlanta, GA.
Live ClinicalTrials.gov results.
Institutions in Atlanta
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 935 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 35 more
- Conditions
- Alzheimer's Disease
- Interventions
- Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 42
- States / cities
- Chandler, Arizona • Garden Grove, California • Long Beach, California + 35 more
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Nipocalimab, Placebo, Standard of care treatment
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 40
- States / cities
- Beverly Hills, California • Hemet, California • La Palma, California + 35 more
- Conditions
- Multiple Myeloma
- Interventions
- Cilta-cel
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2041
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Duarte, California • San Francisco, California + 21 more
- Conditions
- Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
- Interventions
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, Abemaciclib
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2029
- U.S. locations
- 791
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 512 more
- Conditions
- Multiple Myeloma
- Interventions
- Talquetamab, Carfilzomib, Daratumumab SC, Lenalidomide, Pomalidomide
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • San Francisco, California • Denver, Colorado + 8 more
- Conditions
- Multiple Myeloma
- Interventions
- JNJ-79635322
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 24 more
- Conditions
- Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
- Interventions
- Rina-S, IC
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 69
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Irvine, California + 51 more
- Conditions
- HIV -1 Infection
- Interventions
- Every 4-week long-acting injectable cabotegravir and rilpivirine
- Drug
- Lead sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 10
- States / cities
- La Jolla, California • Los Angeles, California • Aurora, Colorado + 7 more
- Conditions
- Metastatic Prostate Cancer
- Interventions
- ARX517, Apalutamide, Abiraterone acetate, Prednisone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 12
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 9 more
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Teclistamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 587 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Duarte, California • Stanford, California + 14 more